Literature DB >> 31583947

The Effect of Including Quantitative Information on Multiple Endpoints in Direct-to-Consumer Prescription Drug Television Advertisements.

Helen W Sullivan1, Amie C O'Donoghue1, Molly Lynch2, Mihaela Johnson2, Christine Davis2, Douglas J Rupert2.   

Abstract

Background. Previous research found that adding a single piece of quantitative information about prescription drug benefits to direct-to-consumer (DTC) ads helps consumers understand how well the drug works. However, drug information often includes quantitative information on multiple benefit outcomes and risks. Thus, we examined whether consumer understanding was similarly improved when DTC television ads include varying amounts of quantitative information. Methods. We randomly assigned participants (945 Internet panelists ≥ 60 years old) to view 1 of 9 fictitious prescription drug television ads that varied the presentation of quantitative information for benefits (none, single outcome, 2 outcomes) and risks (none, 1 risk category, 3 risk categories) and then measured gist and verbatim recall/estimation and drug perceptions. Results. Adding a single benefit outcome and a single risk category replicated past results. Compared with an ad containing no quantitative information, presenting 2 benefit outcomes and multiple risk categories increased gist and verbatim recall and affected drug perceptions. Compared with presenting a single benefit outcome, presenting 2 benefit outcomes increased verbatim recall for the second outcome but decreased verbatim recall for the first outcome. Likewise, compared with presenting a single risk category, presenting multiple risk categories increased gist and verbatim recall for the multiple risk categories but decreased gist recall for a concept more closely associated with the single risk category. Adding multiple risk categories decreased risk perceptions even more than did the single risk category. Limitations. This study may have limited generalizability because it examined an ad for only 1 medical condition. Conclusions. There are tradeoffs to adding multiple quantitative benefit outcomes in DTC ads. However, presenting multiple quantitative risk categories helps consumers better understand a drug's risks.

Entities:  

Keywords:  advertising; direct-to-consumer advertising (DTCA); prescription drug; quantitative; television

Year:  2019        PMID: 31583947      PMCID: PMC7289316          DOI: 10.1177/0272989X19875946

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  34 in total

1.  Effect of Direct-to-Consumer Advertising on Asthma Medication Sales and Healthcare Use.

Authors:  Matthew Daubresse; Susan Hutfless; Yoonsang Kim; Rachel Kornfield; Dima M Qato; Jidong Huang; Kay Miller; Sherry L Emery; G Caleb Alexander
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 21.405

Review 2.  Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations.

Authors:  Isaac M Lipkus
Journal:  Med Decis Making       Date:  2007-09-14       Impact factor: 2.583

3.  Trends in exposure to televised prescription drug advertising, 2003-2011.

Authors:  Rachel Kornfield; G Caleb Alexander; Dima M Qato; Yoonsang Kim; Jan D Hirsch; Sherry L Emery
Journal:  Am J Prev Med       Date:  2015-05       Impact factor: 5.043

Review 4.  Developmental reversals in false memory: a review of data and theory.

Authors:  C J Brainerd; V F Reyna; S J Ceci
Journal:  Psychol Bull       Date:  2008-05       Impact factor: 17.737

5.  Measuring numeracy without a math test: development of the Subjective Numeracy Scale.

Authors:  Angela Fagerlin; Brian J Zikmund-Fisher; Peter A Ubel; Aleksandra Jankovic; Holly A Derry; Dylan M Smith
Journal:  Med Decis Making       Date:  2007-07-19       Impact factor: 2.583

6.  Communicating Benefit and Risk Information in Direct-to-Consumer Print Advertisements: A Randomized Study.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Kathryn J Aikin
Journal:  Ther Innov Regul Sci       Date:  2015-07       Impact factor: 1.778

7.  Communicating the risk of side effects to patients: an evaluation of UK regulatory recommendations.

Authors:  Peter Knapp; David K Raynor; Elizabeth Woolf; Peter H Gardner; Neil Carrigan; Brian McMillan
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Clinical Trial Results Summary for Laypersons: A User Testing Study.

Authors:  D K Raynor; L Myers; K Blackwell; B Kress; A Dubost; A Joos
Journal:  Ther Innov Regul Sci       Date:  2018-02-05       Impact factor: 1.778

9.  Alternative package leaflets improve people's understanding of drug side effects-A randomized controlled exploratory survey.

Authors:  Viktoria Mühlbauer; Roman Prinz; Ingrid Mühlhauser; Odette Wegwarth
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

Review 10.  Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers.

Authors:  Lyndal J Trevena; Brian J Zikmund-Fisher; Adrian Edwards; Wolfgang Gaissmaier; Mirta Galesic; Paul K J Han; John King; Margaret L Lawson; Suzanne K Linder; Isaac Lipkus; Elissa Ozanne; Ellen Peters; Danielle Timmermans; Steven Woloshin
Journal:  BMC Med Inform Decis Mak       Date:  2013-11-29       Impact factor: 2.796

View more
  1 in total

1.  Visual images of prescription drug benefits in direct-to-consumer television advertisements.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Molly Lynch; Mihaela Johnson; Christine Davis; Jacqueline B Amoozegar; Douglas J Rupert
Journal:  Patient Educ Couns       Date:  2021-02-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.